Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

Published:2021-02-11 Issue:2 Volume:4 Page:e2037120
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Sehgal Kartik¹²,Gill Ritu R.³,Widick Page¹,Bindal Poorva¹,McDonald Danielle C.¹,Shea Meghan¹,Rangachari Deepa¹,Costa Daniel B.¹

Affiliation:

1. Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

3. Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2776172/sehgal_2021_oi_201107_1612371664.78093.pdf

Reference20 articles.

1. Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence.;Passaro;J Clin Oncol,2019

2. Prevalence of poor performance status in lung cancer patients: implications for research.;Lilenbaum;J Thorac Oncol,2008

3. Immunotherapy in lung cancer: effective for patients with poor performance status?;Alessi;Lancet Respir Med,2020

4. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.;Reck;N Engl J Med,2016

5. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.;Marur;Semin Oncol,2018

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer;BMC Cancer;2024-08-05

2. Single- and multi-site radiomics may improve overall survival prediction for patients with metastatic lung adenocarcinoma;Diagnostic and Interventional Imaging;2024-08

3. Metastatic Lung Adenocarcinomas: Development and Evaluation of Radiomic-Based Methods to Measure Baseline Intra-Patient Inter-Tumor Lesion Heterogeneity;Journal of Imaging Informatics in Medicine;2024-07-17

4. The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer;Cancer Immunology, Immunotherapy;2024-07-02

5. Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance;Annual Review of Immunology;2024-06-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3